These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28778392)

  • 1. Very long-term serial luminal changes after sirolimus-eluting stent implantation and progression process of very late stent failure.
    Kubo S; Ohya M; Kuwayama A; Shimada T; Miura K; Amano H; Otsuru S; Habara S; Tada T; Tanaka H; Fuku Y; Goto T; Kadota K
    Cardiovasc Revasc Med; 2018; 19(1 Pt B):88-94. PubMed ID: 28778392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in clinical presentations and related angiographic findings among early, late, and very late sirolimus-eluting stent failures requiring target lesion revascularization.
    Kubo S; Ohya M; Kuwayama A; Shimada T; Miura K; Amano H; Hyodo Y; Otsuru S; Habara S; Tada T; Tanaka H; Fuku Y; Goto T; Kadota K
    Int J Cardiol; 2017 Sep; 243():116-120. PubMed ID: 28545849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late catch-up in lumen diameter at five-year angiography in MACE-free patients treated with sirolimus-eluting stents in the Primary Stenting of Totally Occluded Native Coronary Arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II).
    Teeuwen K; Van den Branden BJ; Rahel BM; Laarman GJ; Tijssen JG; Kelder JC; Slagboom T; Ten Berg JM; Suttorp MJ
    EuroIntervention; 2013 Jun; 9(2):212-9. PubMed ID: 23392450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
    Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
    EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
    Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term luminal change after drug-eluting stent implantation: serial angiographic follow-up study of the ZEST randomized trial.
    Park GM; Park DW; Kim YG; Cho SW; Sun BJ; Hwang KW; Kim YR; Ahn JM; Song HG; Kim WJ; Lee JY; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):274-82. PubMed ID: 22431305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
    Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
    JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-stent restenosis is inhibited in a bare metal stent implanted distal to a sirolimus-eluting stent to treat a long de novo coronary lesion with small distal vessel diameter.
    Obata JE; Nakamura T; Kitta Y; Saito Y; Sano K; Fujioka D; Kawabata K; Kugiyama K
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E777-87. PubMed ID: 23378231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
    Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5-7 years) follow-up of the Coronary Revascularization Demonstrating Outcome study-Kyoto registry Cohort-2.
    Natsuaki M; Morimoto T; Furukawa Y; Nakagawa Y; Kadota K; Yamaji K; Ando K; Shizuta S; Shiomi H; Tada T; Tazaki J; Kato Y; Hayano M; Abe M; Tamura T; Shirotani M; Miki S; Matsuda M; Takahashi M; Ishii K; Tanaka M; Aoyama T; Doi O; Hattori R; Kato M; Suwa S; Takizawa A; Takatsu Y; Shinoda E; Eizawa H; Takeda T; Lee JD; Inoko M; Ogawa H; Hamasaki S; Horie M; Nohara R; Kambara H; Fujiwara H; Mitsudo K; Nobuyoshi M; Kita T; Kimura T;
    Circ Cardiovasc Interv; 2014 Apr; 7(2):168-79. PubMed ID: 24550439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: Three-Year Outcomes of the I-LOVE-IT 2 Trial.
    Song L; Li J; Guan C; Jing Q; Lu S; Yang L; Xu K; Yang Y; Xu B; Han Y;
    Catheter Cardiovasc Interv; 2018 Feb; 91(S1):608-616. PubMed ID: 29322619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
    Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
    Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late restenosis following sirolimus-eluting stent implantation.
    Kuriyama N; Kobayashi Y; Nakama T; Mine D; Nishihira K; Shimomura M; Nomura K; Ashikaga K; Matsuyama A; Shibata Y
    JACC Cardiovasc Interv; 2011 Jan; 4(1):123-8. PubMed ID: 21251639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The wound healing response after implantation of a drug-eluting stent is impaired persistently in the long term.
    Nasuno T; Tokura M; Kageyama M; Toyoda S; Sakuma M; Komatsu T; Taguchi I; Abe S; Inoue T
    Heart Vessels; 2016 Jun; 31(6):985-9. PubMed ID: 25939630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.